Cargando…
Loading, please waitCargando…
Loading, please waitConditions
Erectile dysfunction is a medical condition with treatable biological causes — most often vascular, not psychological. Below we explain how ED develops, when stem cells and PRP can realistically help, and how our physicians at Regeneris build a plan around your specific case, your IIEF-5 baseline and your medical history.
Erectile dysfunction (ED) is the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual activity. It is one of the most common medical conditions in men over forty and one of the most reliable early markers of underlying cardiovascular disease. International estimates report meaningful prevalence rates of 30 to 50 percent in men aged 50 to 70, and the incidence rises with age, diabetes, hypertension, smoking and metabolic syndrome.
ED is not a single disease. Clinically it is divided into three main phenotypes — vasculogenic, neurogenic and mixed — with hormonal, drug-induced and psychogenic contributors layered on top. The vast majority of cases in adult men are vasculogenic: the underlying problem is endothelial dysfunction and microvascular disease of the cavernosal arteries, sinusoids and venous occlusive mechanism. Neurogenic ED — most often post-prostatectomy or related to diabetic neuropathy, spinal cord injury or multiple sclerosis — is less common but clinically important because it changes which therapies will actually work.
In the corpora cavernosa, a healthy erection depends on three integrated systems: a robust endothelium that releases nitric oxide, smooth muscle that relaxes in response to nitric oxide and cyclic GMP, and an intact veno-occlusive mechanism against the tunica albuginea. When endothelial cells are damaged by atherosclerosis, hyperglycemia, oxidative stress or chronic inflammation, less nitric oxide is produced; over time, the smooth muscle within the corpora atrophies and is replaced by fibrotic tissue, and the veno-occlusive mechanism leaks. The end result is weaker, less reliable erections — and PDE5 inhibitors that work less well than they used to.
Because ED so often signals broader vascular pathology, an honest evaluation never stops at the symptom. Our protocol at Regeneris Therapy includes a validated IIEF-5 questionnaire to document baseline function, a metabolic and hormonal workup, a frank review of medications and lifestyle, and — when indicated — a penile Doppler ultrasound to characterize arterial inflow and venous leak. Regenerative options are then offered only when the underlying biology suggests they are likely to help.
Erectile dysfunction is a final common pathway with several upstream causes. The dominant mechanism in men over forty is endothelial dysfunction — the same vascular biology that drives coronary disease, peripheral arterial disease and cerebrovascular events. Cardiovascular risk factors that quietly damage the endothelium across the body damage it equally in the cavernosal arteries, where the vessels are smaller and the consequences appear earlier. Hypertension, diabetes, dyslipidemia, central obesity, smoking and obstructive sleep apnea are the classic drivers.
Diabetes deserves special mention. ED prevalence in men with type 2 diabetes is roughly two to three times higher than in non-diabetic peers and tends to appear about a decade earlier. The mechanism is mixed: microvascular disease damages the cavernosal endothelium and small vessels, autonomic neuropathy disrupts the parasympathetic signaling required for smooth-muscle relaxation, and chronic hyperglycemia accelerates non-enzymatic glycation and oxidative stress inside the cavernosal tissue.
Post-prostatectomy ED is a distinct clinical entity. Even with nerve-sparing surgical technique, the cavernous nerves run within millimeters of the prostatic capsule and are vulnerable to traction, thermal or mechanical injury. The result is a neurogenic component superimposed on whatever vasculogenic predisposition the patient already had. Penile rehabilitation protocols that combine PDE5 inhibitors, intracavernosal therapy and — increasingly — regenerative approaches are designed to preserve tissue viability during the months when nerve recovery is still possible.
Other relevant contributors include hypogonadism (low total or free testosterone), thyroid dysfunction, hyperprolactinemia, chronic kidney disease, depression, sleep apnea and a long list of medications: antihypertensives (especially older beta-blockers and thiazides), antidepressants (SSRIs more than others), antipsychotics, finasteride in some patients, opioids and recreational substances. Psychogenic ED — performance anxiety, depression, relationship distress — exists but is less common as a sole cause in men over forty and is often layered on top of a real biological problem.
Regenerative medicine for ED is honest about what it is: an emerging field where the mechanism is strong, the early clinical evidence is promising and the long-term randomized data are still maturing. The goal is to act upstream on the biology of the corpora cavernosa — endothelial function, microvascular density, smooth-muscle preservation and neuro-vascular signaling — rather than only amplifying a fading signal on demand the way PDE5 inhibitors do. The strongest candidates are men with mild-to-moderate vasculogenic ED, often with metabolic risk factors and a declining response to oral medication.
Mesenchymal stem cell (MSC) therapy is the most mechanistically attractive option. MSCs sourced from umbilical cord or adipose tissue act primarily through paracrine signaling: they release growth factors, anti-inflammatory cytokines and extracellular vesicles that promote angiogenesis, support endothelial repair and modulate the local inflammatory milieu. Early-phase clinical trials in men with vasculogenic and diabetic ED — including intracavernosal administration protocols — have reported meaningful improvements in IIEF-5 scores sustained at six and twelve months, with favorable safety profiles. Large multicenter phase III trials are still in progress, and protocol heterogeneity remains a real limitation of the literature.
Platelet-rich plasma (PRP) is autologous: a small blood sample is centrifuged in-clinic to concentrate platelets and the growth factors they release (PDGF, VEGF, TGF-beta, IGF-1, EGF). When delivered as intracavernosal injection, these factors support tissue repair, neovascularization and endothelial recovery. The evidence base for intracavernosal PRP in ED is smaller than for low-intensity shockwave but growing, with randomized trials showing IIEF improvements over placebo in selected cohorts. Its main advantages are excellent safety (autologous), repeatability and reasonable cost; its main limitation is lower regenerative potency per dose than MSC-based protocols.
Low-intensity shockwave therapy (Li-SWT) is the regenerative modality with the most clinical evidence in vasculogenic ED. Focused acoustic pulses generate controlled micromechanical stress in cavernosal tissue, releasing endothelial nitric oxide and activating endogenous angiogenic pathways. Multiple randomized trials and meta-analyses report statistically significant IIEF improvements in mild-to-moderate vasculogenic ED, with effects that can persist 12 to 24 months. It is non-invasive, painless and is frequently used as the foundation onto which PRP or stem-cell-based injections are layered.
In practice we rarely view these modalities as competitors. They act on different parts of the same regenerative cascade and are typically combined — shockwave to prime the tissue, PRP for repeatable autologous support, and selective MSC or exosome application in carefully chosen patients — alongside metabolic optimization, hormonal correction when indicated and a frank conversation about the role of PDE5 inhibitors during the regenerative window.
Linked protocols
Mesenchymal stem cell protocols (intracavernosal and systemic) for selected patients with vasculogenic ED, under COFEPRIS-traceable sourcing.
Autologous platelet-rich plasma — intracavernosal protocols for endothelial repair and neovascularization.
Our combined regenerative protocol for ED: physician evaluation, IIEF-5 baseline, shockwave, PRP and stem-cell options.
Explore regenerative medicine
See the full landscape of treatments we offer in Cancún and the science behind each one.
ED is, in most cases, manageable rather than cured. PDE5 inhibitors restore on-demand function for many men for years; regenerative therapies can improve the baseline biology so that those same men respond more reliably, need lower doses, or — in mild-to-moderate cases — achieve spontaneous erections without medication. The strongest evidence supports IIEF-5 improvements in mild-to-moderate vasculogenic ED. We do not promise definitive results, and any clinic that does should be treated with skepticism.
Timing matters. Tissue regeneration is not an overnight process: clinical improvements after a regenerative protocol typically appear gradually between months two and six and continue to evolve through month twelve, with re-application or maintenance sessions as needed. Outcomes are also strongly influenced by metabolic control: a patient who pairs the protocol with weight management, glycemic control, blood-pressure optimization, smoking cessation and sleep-apnea treatment consistently outperforms one who does not.
Several profiles respond less well, and we say so up front. Severe cavernosal fibrosis or calcification, complete bilateral neurovascular bundle injury after prostatectomy, untreated severe hypogonadism, advanced peripheral arterial disease and primarily psychogenic ED without addressing the underlying psychological factor are all contexts where regenerative therapy alone will not deliver meaningful change. In those cases the appropriate plan may involve intracavernosal pharmacotherapy, vacuum erection devices, a penile prosthesis or psychotherapy — and our job is to tell you that honestly, not to enroll you in a protocol that will not work.
No, and any clinic that frames it that way is not being honest. Stem cells, PRP and shockwave therapy are biologically reasonable approaches to restore cavernosal tissue function rather than to mask symptoms. In appropriately selected patients with mild-to-moderate vasculogenic ED, they can produce meaningful, sustained improvements in IIEF-5 scores and spontaneity, sometimes reducing or eliminating the need for PDE5 inhibitors. We discuss expected outcomes and limitations clearly during your medical consultation.
Revisado por Dra. Claudia Labastida · 2026-05-27
PDE5 inhibitors (sildenafil, tadalafil, vardenafil) work downstream — they amplify the nitric oxide signal the tissue is already producing, on demand, for the duration of the drug. They are excellent medications and remain first-line for most men. Regenerative therapies aim to act upstream by repairing the endothelium and supporting microvascular density, so that the tissue itself recovers function over months. Many patients benefit from a combined approach: regenerative protocol to improve the biology, with PDE5 inhibitors as needed during the regenerative window.
Revisado por Dra. Claudia Labastida · 2026-05-27
The strongest candidates are men with mild-to-moderate vasculogenic ED — typically aged 40 to 70 — who often have metabolic risk factors (diabetes, hypertension, dyslipidemia, central adiposity) and a declining or partial response to PDE5 inhibitors. Patients with primarily neurogenic ED after radical prostatectomy with confirmed bilateral nerve damage, severe cavernosal fibrosis or untreated hypogonadism are evaluated very carefully — the underlying biology may not respond meaningfully to a regenerative approach alone.
Revisado por Dra. Claudia Labastida · 2026-05-27
A typical protocol begins with a comprehensive medical consultation: IIEF-5 questionnaire, hormonal and metabolic workup, medication review and — when indicated — penile Doppler ultrasound. From there, a personalized plan may include several sessions of low-intensity shockwave therapy spaced over weeks, one or more intracavernosal PRP injections under topical or local anesthesia, and in selected patients a dose of mesenchymal stem cells. The full cycle generally extends across two to three months, with IIEF-5 reassessment at three, six and twelve months.
Revisado por Dra. Claudia Labastida · 2026-05-27
Most men describe the sensation as uncomfortable rather than painful. We use topical anesthesia, very fine needles and a slow injection technique to minimize discomfort. The procedure is performed in-clinic in a few minutes, and most patients return to normal activity the same day, with specific guidance about sexual activity and any expected bruising or tenderness over the following days.
Revisado por Dra. Claudia Labastida · 2026-05-27
We measure outcomes objectively. The IIEF-5 (International Index of Erectile Function, short form) is the validated questionnaire we administer at baseline and at three, six and twelve months. We also track changes in spontaneous morning erections, response to PDE5 inhibitors (if you continue them) and, when indicated, repeat penile Doppler studies. Improvements are typically gradual: initial changes appear between weeks 4 and 8, with consolidation between months three and six.
Revisado por Dra. Claudia Labastida · 2026-05-27
Regenerative therapies for ED are generally considered investigational by insurers and are not covered by health insurance plans. We are transparent about pricing during the medical consultation, where we present a written plan with the total investment for the protocol and any expected maintenance sessions. We do not publish blanket prices online because each plan is personalized to the patient's clinical profile and treatment goals.
Revisado por Dra. Claudia Labastida · 2026-05-27
Regeneris Therapy operates under a COFEPRIS aviso de funcionamiento in Cancún and only uses biologics processed in licensed Mexican laboratories with traceability from source to application. Procedures are outpatient, performed by physicians, with documented safety profiles in peer-reviewed literature for shockwave, PRP and early-phase stem cell trials. We coordinate the entire experience — from clinical evaluation to follow-up — for both local and international patients.
Revisado por Dra. Claudia Labastida · 2026-05-27
An honest medical review of stem cell, PRP, and shockwave therapy for erectile dysfunction: mechanisms, clinical evidence, and ideal candidates.
A complete guide to platelet-rich plasma (PRP) therapy: how it works, clinical indications, what to expect, and why it is a popular option in regenerative medicine.
An honest medical review of PT-141 (bremelanotide): CNS mechanism, clinical evidence, comparison with PDE5 inhibitors, dosing, and Mexican regulation.
Knee osteoarthritis (gonarthrosis, ICD-10 M17) is the progressive wear of the cartilage that covers the femur, tibia and patella. At Regeneris Therapy we combine current clinical evidence and regenerative medicine to reduce pain, improve mobility and, in selected cases, postpone or avoid total knee replacement.
Learn about Knee OsteoarthritisLumbar disc herniation (ICD-10 M51.2) occurs when the nucleus pulposus of an intervertebral disc displaces through the annulus fibrosus and compresses neighboring nerve structures. At Regeneris Therapy we combine an honest evaluation, recent imaging and mesenchymal stem cell therapy as a middle path between failed conservative care and surgery — for patients who meet clear clinical criteria.
Learn about Lumbar Disc HerniationFibromyalgia is real, medical and deserves an honest approach. At Regeneris Therapy we combine regenerative medicine, IV therapy and an integrative protocol to help you recover energy, sleep and quality of life — always alongside your rheumatologist.
Learn about Fibromyalgia in Cancún: Symptoms, Causes and Regenerative OptionsNext step
Every plan at Regeneris starts with a physician-led evaluation: IIEF-5 baseline, hormonal and metabolic workup, medication review and — when indicated — penile Doppler. We then recommend the protocol that gives you the best realistic outcome: regenerative, pharmacological, surgical or combined. Book your consultation; we will give you straight answers about whether stem cells, PRP and shockwave are the right fit for your case.